Back to Research Home
SUPNSupernus Pharmaceuticals Inc
Health Care · Biotechnology: Pharmaceutical Preparations · Mid
$40.70−3.26%
As of 23 Oct 2026Mkt cap $2.6B
Stage 13
AVOID
Fundamentals
15.4/75
Technical
5.0/15
Independent
20.4/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- −6.0%
- 3M
- −13.4%
- 6M
- −18.2%
- 1Y
- −19.7%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —Hist median 30.8x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 122.3x
- FCF yield
- 0.8%
Quality
- ROIC
- —
- Operating margin
- -0.9%
- FCF margin
- 6.4%
- Current ratio
- 1.9x
Growth
- Revenue growth
- +8.6%Latest FY YoY
- Revenue CAGR
- +5.5%
- EPS CAGR
- —
- FCF CAGR
- −26.6%
Capital
- Share-count trend
- +0.8%3Y annualised
- Net cash
- $87M-1.8x OCF
Annual trend
- CAGR 2021–2025
- +5.5%
- Latest · 2025
- $1B
- YoY
- +8.6%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded